Germany-based molecular diagnostic company Sysmex Inostics has launched the OncoBEAM RAS CRC test in Italy to assist oncologists in making therapeutic decisions during tissue biopsies.

Centro di Ricerche Oncologiche di Mercogliano (CROM) in Naples was the first centre to have adopted the OncoBEAM RAS test.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Jointly developed by Sysmex Inostics and Merck, the OncoBEAM RAS CRC test determines the RAS mutation status using blood samples.

"The OncoBEAM CRC RAS test can save time, compared with current tissue-based RAS testing."

Assessing of the RAS mutation status in patients with metastatic colorectal cancer (mCRC) has demonstrated the possibility of an improved outcome by anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapies.

CROM pharmacogenomics laboratory director Professor Nicola Normanno said: "In mCRC, RAS is known to be a key biomarker to predict how well mCRC patients may respond to particular treatments, making it important to know their RAS status as early as possible.

See Also:

"The OncoBEAM CRC RAS test can save time, compared with current tissue-based RAS testing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"The liquid biopsy test can also be used as an alternative if tissue for testing is not available."

The test involves a simple method to detect the RAS mutation status of tumours requiring a single blood-draw.

It acts as an alternative to tissue biopsies or other surgical procedures, and can be performed in absence of tumour tissue.

Recent data has displayed that the OncoBEAM RAS CRC can be used to determine the suitability of patients for anti-EGFR therapies, such as Cetuximab.

The test which features 34 KRAS and NRAS mutations aligned to the recommendations of the national comprehensive cancer network (NCCN), European society for medical oncology (ESMO), as well as European Medicines Agency (EMA) guidelines to determine the RAS mutation status before a treatment.